Stockscreener 앱 받기
98.29
0.17%
0.3004
Revolution Medicines Inc 주식(RVMD)의 최신 뉴스
Revolution Medicines, Inc. $RVMD Shares Sold by Allianz Asset Management GmbH - MarketBeat
Revolution Medicines at Guggenheim Biotech Summit: Strategic Focus on RAS Inhibitors - Investing.com Canada
How Revolution Medicines Inc. stock reacts to Fed rate cutsJuly 2025 Macro Moves & Real-Time Volume Analysis - mfd.ru
Stock Traders Purchase High Volume of Put Options on Revolution Medicines (NASDAQ:RVMD) - MarketBeat
Can Revolution Medicines Inc. Equity Warrant stock reach $100 price targetJuly 2025 Action & Accurate Intraday Trade Tips - mfd.ru
Revolution Medicines, Inc. $RVMD Shares Bought by Candriam S.C.A. - MarketBeat
Layoff Watch: Is Revolution Medicines Inc Equity Warrant subject to activist investor interestMarket Risk Summary & Weekly Return Optimization Alerts - baoquankhu1.vn
Update Report: Will Revolution Medicines Inc outperform during market rallies - baoquankhu1.vn
Market Review: Is Revolution Medicines Inc a defensive stockExit Point & Fast Moving Stock Trade Plans - baoquankhu1.vn
Revolution Medicines, Inc. $RVMD Shares Acquired by New York State Common Retirement Fund - MarketBeat
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Revolution Medicines jumps on report AbbVie nears takeover - MSN
Earnings Recap: Is Revolution Medicines Inc affected by consumer sentimentJuly 2025 Reactions & Smart Allocation Stock Tips - baoquankhu1.vn
(RVMD) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - The Manila Times
Revolution Medicines (RVMD) Price Target Increased by 24.66% to 115.71 - Nasdaq
Revolution Medicines (BIT:1RVMD) Price Target Increased by 30.97% to 100.64 - Nasdaq
Bearish Sentiment Observed in Revolution Medicines (RVMD) - GuruFocus
Behind the Headlines Episode 32: AI’s Power, NVIDIA & Lilly, Revolution Medicine - PharmTech.com
Revolution Medicines plummets on report Merck walks from acquisition talks - MSN
The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate - FinancialContent
Revolution Medicines (NASDAQ:RVMD) Price Target Raised to $122.00 - MarketBeat
Revolution Medicines (RVMD) Gets Price Target Boost from JP Morg - GuruFocus
Revolution Medicines, Inc. (RVMD) Stock Analysis: Evaluating the 19.27% Potential Upside in Precision Oncology - DirectorsTalk Interviews
Merck ends talks to buy Revolution Medicines, WSJ reports - MSN
Knights of Columbus Asset Advisors LLC Takes $587,000 Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Why Revolution Medicines stock plummeted by almost 17% today - MSN
Revolution Medicines stock stares at big dip after Merck reportedly shelves buyout — but analyst flags opportunity - MSN
Merck is said to halt acquisition talks with cancer drug developer Revolution - MSN
Market Outlook: Is now the right time to enter Revolution Medicines IncWeekly Investment Recap & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Merck Ends Revolution Talks As Oncology Focus And Valuation Take Center Stage - Sahm
RVMD stock tumbles as MRK reportedly withdraws buyout offer - MSN
Revolution Medicines shares slide after Merck reportedly walks away from takeover talks - MSN
What is Revolution Medicines Inc.’s market positionWeekly Profit Recap & High Conviction Investment Ideas - mfd.ru
Revolution Medicines (RVMD) Initiates First Human Trial for RMC-5127 - GuruFocus
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor - GlobeNewswire
48,000 RAS G12V cancer cases a year as Revolution Medicines trials new drug - Stock Titan
Y Intercept Hong Kong Ltd Has $2.58 Million Stock Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Analysts Offer Insights on Healthcare Companies: Tonix Pharma (TNXP), Revolution Medicines (RVMD) and Bausch Health Companies (BHC) - The Globe and Mail
Merck Ends Revolution Medicines Talks As Oncology Plans And Valuation Weighed - Yahoo Finance
Oppenheimer Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $150 - 富途牛牛
RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer - Yahoo Finance
Truist Financial Initiates Revolution Medicines(RVMD.US) With Buy Rating - 富途牛牛
Oppenheimer Raises Price Target for Revolution Medicines (RVMD) - GuruFocus
Revolution Medicines (RVMD) Dives 16.9% as Merck Withdraws Takeover Plan - Insider Monkey
10 Big Names Stumbling Hard - Insider Monkey
Revolution Medicines Shares Plunge 17% After Merck Acquisition Talks Stall - Intellectia AI
Why Revolution Medicines Stock Plummeted by Almost 17% Today - Finviz
Why Revolution Medicines Stock Plummeted by Almost 17% Today - The Motley Fool
Revolution’s shares dip with report of Merck walking away: Deals Report - biocentury.com
Merck stock slips after report says MRK stepped back from Revolution Medicines talks - TechStock²
MSD Reportedly Ends Takeover Talks with Revolution Medicines - marketscreener.com
Revolution Medicines (NASDAQ:RVMD) Shares Gap DownTime to Sell? - MarketBeat
Aug Chart Watch: Is Revolution Medicines Inc. stock undervalued right nowJuly 2025 Recap & AI Optimized Trade Strategies - baoquankhu1.vn
Merck Chooses Evolution Over RevolutionAt Proposed Price, I'm Not Surprised (NYSE:MRK) - Seeking Alpha
Merck, negotiations to acquire biotech Revolution Medicines stalled - Il Sole 24 ORE
Merck Ends Acquisition Talks With Revolution Medicines After Valuation Dispute - Yahoo Finance
1.67%
2.63%
자본화:
|
볼륨(24시간):